entecavir + tenofovir disoproxil fumarate + tenofovir alafenamide + TMF

This is a **combination regimen** consisting of four antiviral agents: entecavir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and TMF (TMF is not clearly defined in the provided context, and based on current pharmaceutical databases and recent literature, TMF could sometimes refer to tenofovir amibufenamide or other investigational nucleotide analogues, but this is uncertain—see comments). **Entecavir, TDF, and TAF** are nucleoside/nucleotide analogues that inhibit the replication of hepatitis B virus (HBV) by interfering with viral DNA polymerase, effectively blocking the reverse transcription process crucial for HBV replication[1][2][4][5][6]. **Entecavir** is a guanosine nucleoside analogue; **TDF** and **TAF** are prodrugs of tenofovir, an adenosine nucleotide analogue. These drugs have high genetic barriers to resistance and are effective in patients with chronic HBV, including those with resistance to other antivirals[1][4][5][6]. **Combination regimens** with these agents are primarily explored for **multidrug-resistant HBV** or in cases where resistance mutations reduce the efficacy of monotherapy. TMF's addition suggests investigational or pipeline combinations for HBV, possibly aiming to further reduce resistance or improve safety/tolerability profiles.

Brand names

BaracludeVemlidyVireadHengmu

Other names

ETV/TAF/TDF/TMFREASON Study treatment regimen